Related Experiment Video
Updated: Apr 11, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Analyzing resistance pattern of non-small cell lung cancer to crizotinib using molecular dynamic approaches
Abstract:
Crizotinib is the potential anticancer drug used for the treatment of non-small cell lung cancer (NSCLC) approved by FDA in 2011. The main target for the crizotinib is anaplastic lymphoma kinase (ALK). Evidences available indicate that double mutant ALK (L1196M and G1269A) confers resistance to crizotinib. However, how mutation confers drug resistance is not well-understood. Hence, in the present study, molecular dynamic (MD) simulation approach was employed to study the impact of crizotinib binding efficacy with ALK structures at a molecular level. Docking results indicated that ALK double mutant (L1196M and G1269A) significantly affected the binding affinity for crizotinib. Furthermore, MD studies revealed that mutant ALK-crizotinib complex showed higher deviation, higher fluctuation and decreased number of intermolecular H-bonds, when compared to the native ALK-crizotinib complex. These results may be immense importance for the molecular level understanding of the crizotinib resistance pattern and also for designing potential drug molecule for the treatment of lung cancer.
Insights
Double mutations in anaplastic lymphoma kinase (ALK) confer resistance to the anticancer drug crizotinib. Molecular dynamic simulations reveal these mutations disrupt drug binding and stability, offering insights into lung cancer treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Computational Chemistry
Background:
- Crizotinib, an anticancer drug approved in 2011, targets anaplastic lymphoma kinase (ALK) for non-small cell lung cancer (NSCLC) treatment.
- Emerging evidence suggests that specific double mutations in ALK (L1196M and G1269A) lead to acquired resistance to crizotinib.
- The precise molecular mechanisms by which these ALK mutations confer drug resistance remain incompletely understood.
Purpose of the Study:
- To investigate the molecular basis of crizotinib resistance in non-small cell lung cancer (NSCLC) driven by ALK mutations.
- To elucidate the impact of ALK double mutations (L1196M and G1269A) on crizotinib binding affinity and complex stability.
- To provide a molecular-level understanding that can aid in the design of next-generation ALK inhibitors.
Main Methods:
- Utilized molecular docking to assess the binding affinity of crizotinib to both wild-type and double-mutant ALK structures.
- Employed molecular dynamics (MD) simulations to analyze the dynamic behavior and stability of ALK-crizotinib complexes.
- Quantified changes in complex deviation, atomic fluctuations, and intermolecular hydrogen bonding in mutant versus native complexes.
Main Results:
- Docking analyses demonstrated a significant reduction in binding affinity of crizotinib to the ALK double mutant (L1196M and G1269A) compared to the wild-type.
- Molecular dynamics simulations revealed increased structural deviation and atomic fluctuations in the mutant ALK-crizotinib complex.
- A notable decrease in the number of intermolecular hydrogen bonds was observed in the mutant complex, indicating weakened drug-target interactions.
Conclusions:
- The ALK double mutations L1196M and G1269A substantially impair crizotinib's binding efficacy and complex stability.
- These findings provide critical molecular insights into the mechanisms underlying crizotinib resistance in NSCLC patients.
- The study's results are valuable for developing novel therapeutic strategies and drug candidates to overcome resistance in lung cancer treatment.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
